Share on StockTwits

Equities research analysts at Investec boosted their target price on shares of Consort Medical plc (LON:CSRT) from GBX 1,005 ($17.06) to GBX 1,021 ($17.33) in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. Investec’s price objective points to a potential upside of 16.02% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Consort Medical plc in a research note on Tuesday. They now have a GBX 1,000 ($16.98) price target on the stock. Separately, analysts at N+1 Singer upgraded shares of Consort Medical plc to a “buy” rating in a research note on Tuesday. They now have a GBX 1,020 ($17.31) price target on the stock. Finally, analysts at FinnCap reiterated a “sell” rating on shares of Consort Medical plc in a research note on Tuesday. They now have a GBX 690 ($11.71) price target on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of GBX 942.50 ($16.00).

Consort Medical plc (LON:CSRT) opened at 899.00 on Tuesday. Consort Medical plc has a 52 week low of GBX 773.00 and a 52 week high of GBX 1113.00. The stock has a 50-day moving average of GBX 878.5 and a 200-day moving average of GBX 942.. The company’s market cap is £258.6 million.

Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.